

Dedications

To my husband and family,

To Kuku Dairy producers

and those who suffered From Brucellosis

I dedicate this work.

Khansaa

ACKNOWLEDGEMENTS

First, Thank God who gave me the patience, ability and strength to complete this work.

I was told before I came to work with Prof Mohamed Hashim Awad and Prof Babikir Alhaj that they did not tolerate "tomfoolery." Accordingly, I must convey gratitude to my supervisors for years of academic guidance, and the occasional "tomfoolery"-correction. For patient and valuable recommendations throughout this work.

Drs J. Zinsstag And Felix Roth from Swiss Tropical Institute provided unlimited support through their analytical model and other materials, without which this work could not have been presented in this manner.

The Ministry of Agriculture -Khartoum state- and the University of Sudan of Science and Technology contributed in funding. Special thanks are due to Dr.Faisal Hassan Ibrahim Minister of Agriculture, Animal resources and Irrigation- Khartoum State, Dr. Babikir Ateiya Kuku Scheme Director, Dr. Abdelwahid Mohamed Sharif General director of Animal Resources as well as Dr. Deyaa Eldeen Hassan Planning department.

I would like also to thank Staff members of The National Health Laboratory, first for their sincere collaboration in permitting me to utilize all their facilities and for their friendly attitude. Special thanks are extended to Dr. Nageeb Suliman Saeed, the General Manager of The National Health Laboratory not only for his great help but also for contacting colleagues to provide help. In this respect Prof. Musa Mohammed Khair of Faisal Professional Private Clinic was the Physician who examined the infected

persons, cardinal gratitude on behalf of the patients and myself are extended to him.

The National Veterinary laboratory- Department of Brucella Provided the Rose Bengal antigen. Drs Rageb Mohammed Bakheit, Enaam Alsanossi and Nawaai contributed much in this respect . The Advice and Support of Prof. Osman Saad, and Dr. Fegiri were greatly appreciated.

I deem it a privilege to express my cardinal gratitude to Prof. Musa Tibin Ministry of Science and technology, Dr Hassan Mohammed Nur Ministry of animal resources and Prof . Ahmed Ali Ismail University of Sudan of Science and Technology for their kind help, precious devotion and encouraging suggestions.

I owe thanks to colleagues in the private sector as well as the people of Kuku Scheme Dr Zubeeda ,Neama , Dr. Altaeib Alnour ,Osman , Hamid Samuel and Bekri.

My Younger brother and colleague Adil Abderahman created a stimulating environment. He and Miss Zenab were incredible in their dedication to this work.

Most importantly, my family has all sacrificed so that I could be a student:

My mother, husband, Anfal ,Amel, Sami, Amin, Rawan Elnour and Aam . I can never repay that debt.

ABSTRACT

The objective of this research is to quantify the impact of Brucellosis on Kuku Dairy scheme. Ecozoo model with introduction of some modifications was used as analytical framework. It provides the information needed to analyze the epidemiology of the disease in both animals and humans as well as the economic analysis. Epidemiological data required were obtained from primary sources. These include two seroprevalence surveys for cattle, personal communications were also used as a source of primary data.

Two field surveys (including seroprevalence and socioeconomic surveys) were conducted during the period Jan- June 2004 . The Humans Brucellosis survey included 176 Volunteers from the population at risk. In the Bovine Brucellosis survey the sample design was based on two stages random sample design. In the first stage, holdings (the primary statistical units) were identified. Then the individual Animals (the Secondary Statistical units) were selected. The size of the primary Statistical units was calculated as 30.1 with $\alpha = 0.05$ and desired accuracy of (10) . The number of animals examined was 574.

The laboratory diagnosis relied mainly on serological tests namely Rose –Bengal Test (RBT) as screening test and Competitive Enzyme linked Immuno- Sorbent Assay (cELISA) as confirmatory test. Tube agglutination test (TAT) was used as a routine test.

According to the confirmatory test : the herd prevalence rate is 90%, individual animal prevalence rate 24.9% and average within herd prevalence rate 24.5% (Sd 15.7 CI 4.088 at 95%). Based on c-Elisa human prevalence rate is 11.3% considering the seropositivity and 2.8% considering active brucella infection. Based on prevalence rates estimates on human parameters was found to be 18 active infected person in the baseline year and the infected cattle are 1508 head. These parameters were introduced into Ecozoo model. Data for DALYs calculation were obtained from primary sources as well as secondary sources.

Based on the epidemiological and economic data the total cost of the disease in both dairy and health sectors was found to be 67126953.8 SD out of which 66910503.8 SD was the cost of the dairy sector and 216450SD was the cost of health sector. Accordingly, the dairy sector Shouldered 99.76 % of the cost, while the health sector Shouldered 0.33% of Brucellosis cost in the base line year.

The burden of the disease was measured in DALYs. In the baseline year 18 persons were infected with Brucellosis . If we considered Brucellosis associated with level 0.1-disability weight, every infected person will loose 0.392659 year of his healthy life as a result of the infection. The total infected people will loose 7.067862 years of their healthy life. If the disease associated with level 0.2 disability weight, every infected person will loose 0.785318 years and the whole infected people will loose 14.13572 years of their healthy life.

Evolution of the disease over 11 years was investigated in two scenarios. In scenario 1 the total animal population was left to grow at the normal rates. In this case the number of seropositive animals will increase with growth rate of 103.2% followed by the increase in number of actively infected humans with growth rate of 27.8%.

The total cost of the disease in both dairy and health sectors were found to be 1022123020SD (745547286 SD in PV) equivalent to 4088492.08 US\$ over the 11 years.

The total loss of healthy years over the 11 years will account to 59.7 years (0.1 DW). And 119.4 years (0.2 DW).

In Scenario 11 the total number of animals was held constant. In this case the number of seropositive animals will increase during the 11 years with growth rate of 258.1% Followed by the increase in number of actively infected humans with growth rate of 133%. The total cost of the disease in both dairy and health sectors was found to be 1414827570 SD (101505075 in PV) equivalent to 5655170.142US\$ over the 11 years.

The total loss of healthy years over the 11 years will account to 89.1 years (0.1 DW). And 178.3 years (0.2 DW).

Most of the producers (80%) are well informed about the disease and its zoonotic nature, (53%) are well acquainted with the economic importance of the disease. All of them Support the idea of disease control.

The study confirm the endimicity of the scheme with both human and bovine Brucellosis.and prove the economic loss due to disease both financial and its burden on human heath.

The study recommends intervention to control the disease. Adoption of Whole herd Vaccination policy was recommended. Simulation of different intervention strategies to analyze the cost and benefits will help policy makers in setting up their priorities

الخلاصة

استهدفت الدراسة تقدير الخسائر الناتجة عن تفشي مرض البروسيلوزس بمشروع ألبان كوكو. استخدمت الدراسة نموذج ال Ecozoo مع إجراء بعض التعديلات كأداة للتحليل. تم الحصول على البيانات المطلوبة من مصادرها الأولية والثانوية. للحصول على البيانات الأولية تم إجراء مسحين حقلين لجمع بيانات عن بر وسيلا الإنسان وآخر عن بر وسيلا الأبقار. أيضا تم استخدام أسلوب المقابلة الشخصية مع المنتجين و الخبراء لجمع البيانات الأولية. تم إجراء مسح بر وسيلا الإنسان في الفترة ما بين يناير إلى يونيو 2004 حيث جمعت عينات للدم من 176 متبرع بالإضافة الى البيانات المطلوبة. اعتمد التشخيص المعمل على اختبارات المصل بالتحديد اختبار الـ روز بنغال ككاشف مسحي واختبار c-ELISA كاختبار تأكيدي. أخضعت العينات أيضا لاختبار TAT اختبار روتيني يجرى بالسودان. لتقدير عبء المرض على الإنسان تم استخدام مؤشر غير نقدي (زمني) يعرف بسنوات التعطيل المعدلة . بالنسبة لبر وسيلا الأبقار تم اختيار العينة على مرحلتين ، في المرحلة الأولى تم اختيار الحيازات (القطعان) عشوائيا. في المرحلة الثانية تم اختيار الوحدات الإحصائية (الحيوانات). استهدفت الدراسة كل الأبقار البالغة. بلغ عدد الحيازات المختارة 30 حيازة بينما بلغ عدد الأبقار 574 . حيث تم اخذ العينات وفحصها بواسطة اختبار الـ روز بنغال و c-ELISA .

فيما يتعلق بانتشار المرض توصلت الدراسة الى النتائج التالية:

بلغ معدل انتشار المرض فى الانسان 11.3%. بناء على ايجابية اختبار المصل و2.8% بناء على الإصابة الحقيقية.

بالنسبة للأبقار بلغ معدل انتشار المرض فى القطعان 90%، معدل الانتشار بين الأبقار 24.9% ومتوسط معدل الانتشار داخل القطيع 24.5%.

بناء على هذه المعدلات بلغ تقدير عدد الأشخاص المصابين فى سنة الأساس 18 شخصا وعدد الأبقار المصابة 1508. بلغ تقدير الخسائر الناجمة عن المرض ب67126953.8 دينار (سبعة وستون مليوناً ومائة وستة وعشرون ألفاً وتسعمائة ثلاث خمسون ديناراً). منها 66910503.8 دينار (ستة وستون مليوناً وستمائة وعشرة ألفاً وخمسمائة وثلاث ديناراً) خسائر قطاع الألبان بينما بلغت الخسائر فى قطاع الصحة 216450 (مائتان وأربعة عشر ألفاً وأربعمائة وخمسون ديناراً). عليه فان قطاع الألبان يتحمل 99.76% من تكلفة المرض بينما يتحمل قطاع الصحة 0.33% من التكلفة.

فيما يتعلق بالعبء الصحى على الإنسان، توصلت الدراسة الى أن الفرد المصاب يفقد 0.392659 من سنوات عمره المعافاة اذا ارتبط المرض بوزن التعطيل 0.1، و 0.785318 سنة إذا ارتبط المرض بالوزن 0.2، وعليه يبلغ عدد سنوات العمر المعافاة النى يفقدها المصابون فى الحالة الأولى 7.067862 سنة و 14.13572 سنة فى الحالة الثانية.

بحثت الدراسة تطور المرض خلال 11 سنة من خلال سيناريو هين ، فى السيناريو الاول ترك العدد الكلى للحيوانات ينمو وفق المعدلات الجارية. فى هذه الحالة فان عدد الحيوانات المصابة سوف ينمو بمعدل 103.2% و ينمو عدد الأفراد المصابين بمعدل 27.8% وتكون تكلفة المرض الكلية فى خلال إحدى عشر سنة (2004-2014) 1022123020 دينار 745547286 دينار بالقيمة الحالية. ما يعادل 4088492.08 دولار .

بلغ عدد سنوات العمر المعافاة المفقودة إحدى عشر سنة 59.7 سنة بوزن 0.1 و119.4 سنة بوزن 0.2 .

أجرى السيناريو الثانى بافتراض ثبات العدد الكلى للحيوانات. فى هذه الحالة فان عدد الحيوانات المصابة سوف يزيد بمعدل 258.1% فى خلال إحدى عشر سنة بينما يزيد عدد الأفراد

المصابين أصابه فعليه 133% . تبلغ التكلفة الكلية للمرض 1414827570 دينار
SD101505075 دينار بالقيمة الحالي. ما يعادل 5655170.142 دولار .
يقدر الفقد الكلى لسنوات العمر المعافاة ب 89.1 سنة بوزن 0.1 و 178.3 بالوزن 0.2 . توصلت
الدراسة الى أن معظم المنتجين (80%) لديهم العلم الكافي بالمرض وطبيعته المعدية للإنسان. وأن
(53 %) منهم يدركون أهميته الاقتصادية. أكدت الدراسة استيطان المرض بالمشروع وأثبتت
الخسائر الناجمة عنه. كما أوضحت تطور المرض والخسائر الناتجة عن ذلك عند عدم السيطرة عليه
فى خلال إحدى عشر سنة . أوصت الدراسة بالتدخل للسيطرة على المرض فى الحيوان وذلك بإتباع
سياسة التطعيم الكلى للقطيع ثم تطعيم العجول سنويا والحيوانات البالغة كل سنتين لمدة عشر سنوات
ثم إتباع سياسة الفحص وذبح الحيوانات الموجبة . وذلك بعد مضاهاة الاستراتيجية المختارة
بمعدلات مختلفة لكفاءة المصل لتحديد نسبة التكاليف والمنافع مما يساعد متخذي القرار فى اختيار
البديل المناسب .

TABLE OF CONTENTS

Content	Page
<i>Dedications</i>	
<i>1th</i>	
<i>Acknowldegements</i>	
<i>2th</i>	
<i>English abstrac t</i>	
<i>4th</i>	
<i>Arabic abstract</i>	
<i>5th</i>	
<i>Table of Contents</i>	
<i>10th</i>	
<i>List of Tables</i>	
<i>15th</i>	
<i>List of Figures</i>	<i>18</i>
<i>th</i>	

List of abberiviations

19th

List of Map s

21th

List of appendices

22th

Chapter One: Introduction

1

1-1 Background

1

1-2 Dairy sub-sector in Sudan

4

1-3 Problem statement

6

1-4 Rationale of the Research

7

1-5 The Research Objectives

7

1-6 The research hypotheses

8

1-7 Time and place of the research

8

1-8 Research layout

8

Chapter Two: Literature Review

2.1.1 Animal heath economic

10

2.1. 2 . Economics of animal health.

16

1.2. The burden of disease.

19

2.2.1. Disability adjusted life years (DALYS).

20

2.2.2.	Calculating DALYs.	22
2.2.3.	Calculation of DALYS with discounting and age weighting.	23
2-3	Zoonosis.	25
2.4	Brucellosis.	26
2.4.1	Economic importance of brucellosis	28
2.4.2.	Bioterrorism of Brucella	29
2.4.3	Bovine Brucellosis	30
2.4.3.1	Epizootiology of Bovine Brucellosis	30
2.4.3.2.	Transmission in animals	31
2.4.3.3.	Clinical signs	32
2.4.3.4.	Diagnosis of Bovine Brucellosis	33
2.4.3.5.	Treatment of Bovine Brucellosis	37
2.4.3.6.	Control and Eradication of Bovine Brucellosis	38
2.4.3.7.	A review of some control programs	42
2.4.4.	Human Brucellosis	45
2.4.4. 1.	Historical Background	45
2.4.4. 2.	Epidemiology of Human Brucellosis	46
2.4.4. 3.	Transmission of Human Brucellosis	47
2.4.4. 4.	Clinical signs of Human Brucellosis	48
2.4.4. 5.	Pathogenesis of Human Brucellosis	49
2.4.4. 6.	Diagnosis of Human Brucellosis	51
2.4.4. 7.	Medications	53
2.4.4. 8.	Control Measures	54
2.4.5.	Brucellosis in Sudan	54
2.4.6.	Experience of Arab Company for Agricultural Production and	56

	Processing (ACAPP) in eradication of bovine brucellosis	
2.4.7.	Relevant studies	57
2.4.7. 1.	Bovine Brucellosis	57
2.4.7. 2.	Human Brucellosis	59
2.4.8.	Economic assessments of Brucellosis	62
	<i>Chapter Three: Materials and Methods</i>	64
3-1	The study area	64
3-2	The methodology of data collection	67
3-2-1	Primary Data	68
3-2-1-1	Data collection concerning Bovine Brucellosis	69
3-2-1-2	Data collection concerning Human Brucellosis	71
3-3-	Laboratory diagnosis	73
3-4	The analytical framework	78
3-4-1	The Ecozoo Model	78
3-4-2	Kuku model as a modification of Ecozoo	83
3-5	Computations	88
	<i>Chapter Four : Results</i>	91

4-1	Bovine Brucellosis:	91
4-1-1	The Sample Size and design	91
4-1-2	The Study population	91
4-1-3	Prevalence of Bovine Brucellosis	92
4-1-3-1	Screening rate using RBT	92
4-1-3-2	Confirmation rates in c-Elisa for RBT positive samples	92
4-1-4	Fitting Data to the deterministic-transmission model	94
4-2	Human Brucellosis	95
4-2-1	The sample size:	95
4-2-2	The study population`	95
4-2-3	Prevalence of Human Brucellosis	95
4-2-3-1	Screening rate using RBT	95
4-2-3-2	Confirmation rates in c-Elisa	96
4-2-3-3	Confirmation rates in TAT	96
4-3	Fitting data to the model	98
4-3-1	Baseline year estimates:	98
4-3-1-1	Cost of Brucellosis in the dairy Sector	99
4-3-1-2	Impact of Brucellosis on health sector	100
4-3-1-3	Cost Sharing between the two Sectors	101
4-3-1-4	The burden of human brucellosis in kuku scheme in DALYS	102
4-4	Evolution of the disease over 11 years	103
4-4-1	Scenarios 1	103
4-4-1-1	Impact of Brucellosis	110
4-4-1-1-1	Impact of Brucellosis on dairy sector	110
4-4-1-1-2	Impact of Brucellosis on Health sector	111

4-4-1-1-3	Impact of Brucellosis on Dairy and Health sectors	112
4-4-1-1-4	The burden of Brucellosis	112
4-4-2	Scenario 11	113
4-4-2-1	Impact of Brucellosis:	119
4-4-2-1-1	Impact of Brucellosis on dairy sector	119
4-4-2-1-2	Impact of Brucellosis on Health sector	121
4-4-2-1-3	Impact of Brucellosis on Dairy and Health sectors	122
4-4-2-1-3	The Burden of Brucellosis	123
4-5	Producer knowledge about the disease and their attitude towards disease control	124

Chapter five : Discussion **126**

5-1	Prevalence of Bovine Brucellosis	126
5-2	Prevalence of Human Brucellosis	128
5-3	The Model	129
5- 4	Evolution of Bovine Brucellosis over 11 years (scenario 1)	132
5-5	Evolution of Human Brucellosis over 11 years scenario 1)	133
5-6	Impact of Brucellosis:	134
5-7	The burden of Brucellosis in Kuku scheme:	135
5-8	Control of bovine Brucellosis in Kuku scheme:	136

138

Chapter six: Conclusions and recommendations

References

Appendices

LIST OF TABLES

<i>Table</i>	<i>content</i>	
<i>page</i>		
Table 1-1	Estimated milk production in Sudan (2004)	5
Table 1-2	Milk gap from domestic production	5
Table 1-3	Quantity and Value of Milk products import 1999-2001	6

Table 4-1	Herd Composition in Kuku dairy Scheme	92
Table 4-2	Herd prevalence in kuku Scheme based on RBT & c-Elisa	92
Table 4-3	Individual Animal prevalence in kuku Scheme based on RBT& c-Elisa	94
Table 4- 4	Screening test (RBT) results of human sera	96
Table 4- 5	Confirmatory rates of human sera in c-Elisa	97
Table 4- 6	Confirmatory rates of human sera in TAT	97
Table 4- 7	Confirmatory rates of C-elisa and TAT on RBT	98
Table 4- 8	Baseline estimates for brucellosis deterministic transmission model between cattle and from cattle to humans	98
Table 4-9	Quantity &Value of milk lost due to Brucellosis in Kuku cooperative scheme in the baseline year (2004)	99
Table 4-10	Number & Value of meat lost due to Brucellosis in Kuku cooperative scheme in the baseline year (2004)	100
Table 4- 11	Total losses due to Brucellosis in the Dairy Sector	100
Table 4-12	The Financial cost of Human Brucellosis in the baseline year	101
Table 4-13	Cost Sharing between dairy and Health sectors	102
Table 4-14	The burden of Human Brucellosis in Kuku Scheme in Dalys	
Table 4-15	Estimated Parameters of Brucellosis transmission	104

between Cattle and from cattle to humans in kuku
Scheme

Table 4-16	Evolution of Bovine Brucellosis in kuku scheme over 11 year (2004-2014) with growing animal population	105
Table 4-17	Growth rates of Susceptible, Seropositive and total animal population in 11 years	107
Table 4-18	Evolution of human brucellosis over 11 years (2004-2014) with growing animal population	108
Table 4-19	Growth rates of Susceptible, infected, immune and in contact human in 11 years	108
Table 4-20	Value of milk and calves lost due to Brucellosis In Kuku cooperative scheme over 11 years	110
Table 4-21	Present value of milk and calves lost due to brucellosis in Kuku cooperative scheme over 11 years	111
Table 4-22	Cost of Brucellosis to health Sector	111
Table 4- 23	The total cost of Brucellosis in Dairy & Health Sector over 11 years	112
Table 4-24	The burden of Human Brucellosis over 11 years in Kuku scheme (Scenario 1)	113
Table 4-25	Evolution of Bovine Brucellosis in kuku scheme over 11 year with constant animal population	115
Table 4-26	Growth rates of Susceptible, seropositive and total animal population in 11 years	116
Table 4-27	Evolution of Human Brucellosis over 11 year with	116

	Constant animal population	
Table 4-28	Growth rates of Susceptible, infected, immune and in contact human in 11 years with constant animal population	119
Table 4-29	Value of milk and calves lost due to Brucellosis in Kuku cooperative scheme over the 11 years	120
Table 4-30	Present value of milk and calves lost due to Brucellosis in Kuku cooperative scheme over 11 years	121
Table 4- 31	Cost of Brucellosis in health Sector	122
Table 4- 32	Cost of Brucellosis in Dairy and Health Sectors in Kuku cooperative scheme over 11 years	123
Table 4- 33	The burden of Human Brucellosis in Kuku scheme with constant animal population	124

LIST OF FIGURES

<i>Figure</i>	<i>contents</i>	<i>page</i>
Fig. 1	Kuku deterministic transmission model	87
Fig. 2	Herd composition in Kuku scheme	93
Fig. 3	Individual Animal prevalence in kuku Scheme based on RBT& c-Elisa	93
Fig. 4	Results Of humans sera in RBT, C-Elisa and TAT	93
Figure 5a	Evolution of Bovine Brucellosis in Kuku Scheme over 11 years (2004-2014) with growing animal population	106
Figure 5b	Incidence of bovine brucellosis and the change in the number of Susceptible and Seropositve animals over 11 years (2004- 2014)with growing animal population	106
Fig. 6a	Evolution of human Brucellosis in Kuku scheme over 11 years(2004-2014) with growing animal	109
Fig. 6b	Change in the number of susceptible, infected and Immune humans in Kuku scheme over 11 years with growing animal population	109
Fig. 7a	Evolution of Bovine Brucellosis in Kuku scheme over 11 years (2004-2014) with constant animal population	114
Fig. 7b	Incidence of Bovine Brucellosis and change in the number of Susceptible and seropositive animal with constant animal population	114
Fig. 8a	Evolution of human Brucellosis in Kuku scheme over	118

11 years (2004-2014) with constant animal population

Fig. 8b Change in the number of susceptible, infected and Immune humans in Kuku scheme with constant animal population 118

LIST OF ABBREVIATIONS

ACAPP	Arab Company for Agriculture production and processing
ASA	Applied science and analysis
BBAT	Buffered Brucella antigen tests
BEP	Brucellosis Eradication Program
BTB	Bovine tuberculosis
Cc	Conjugate control
c-ELISA.	Competitive Enzyme Linked Immuno- sorbent Assay.
CDC	The Centers for Disease Control and Prevention
CNS	Central Nervous System
CF	Complement fixation
DALYs.	Disability-adjusted life years
Defra	Department for Environmental, Food and Rural Affairs
DW	Disability weight
DBMD	Division of Bacterial and Mycotic Diseases
FAO	Food and Agriculture Organization
GATT	General agreement on Trade and Tariff
GU	Genitourinary

H2O2	Hydrogen peroxide
HR P	Horse- radish peroxidase
IELISA	Indirect Enzyme Linked Immuno- sorbent Assay
ICFTU	International Complement Fixation Unit
IM	Intra muscular
IMI	intramammary infusion
IV	Intravenous
KCDFs	Kuku cooperative dairy farms
LA-OTC	long-acting oxytetracycline
LDCs	Less developing countries
LDPS	livestock development planning system
M.D	Medical Doctor
MAb	Monoclonal. Antibody
MMWR	Mortality and Morbidity Weekly Report
MRT	Milk Ring Test
OD	Optical density
OIE	Office International des Epizooties
OIEISS	OIE International Standard System
PBS	Phosphate buffer saline
PCR	polymerase chain reaction
PI	percentage inhibition
PO	Per Oss
PP	per cent positivity
RBSA	Rose-Bengal slide agglutination

RBT	Rose –Bengal Test
SAT	Serum agglutination test
S-LPS	Smooth Lipopoly Saccaride
ST	streptomycin
STA	Standard tube agglutination
TAT	Tube Agglutination Test
TMP-SMZ	trimethoprim/sulfamethoxazole
WHO	World Health Organization
WTO	World Trade Organization

LIST OF MAPS

Map	page
1- The Republic of Sudan	65
2- Khartoum State	66

LIST OF APPENDICES

- Appendix 1 Bovine Brucellosis distribution Table
- Appendix 2 Questionnaire sheet for bovine brucellosis survey in Kuku
 Dairy Co-operative Scheme, Khartoum North, Sudan,
 2004.
- Appendix 3 Data included in individual cow Master sheet
- Appendix 4 Data included in Human brucellosis Master sheet.
- Appendix 5 Sources of data.
- Appendix 6 The animals sample size.

- Appendix 7 Model for joint human-animal brucellosis transmission in Mongolia after Roth et al., (2003), with permission from the Bulletin of the World Health Organization.
- Appendix 8 Differential equations for the fitting and simulation of vaccination.
- Appendix 9 Evolution of Bovine Brucellosis in Kuku dairy Scheme with growing animal population
- Appendix 10 Evolution of Human Brucellosis in Kuku dairy Scheme with growing animal population
- Appendix 11 Evolution of Bovine Brucellosis in Kuku dairy Scheme with Constant animal population
- Appendix 12 Evolution of Human Brucellosis in Kuku dairy Scheme with Constant animal population

Dedications

To my husband and family,

To Kuku Dairy producers

and those who suffered From Brucellosis

I dedicate this work.

Khansaa

ACKNOWLEDGEMENTS

First, Thank God who gave me the patience, ability and strength to complete this work.

I was told before I came to work with Prof Mohamed Hashim Awad and Prof Babikir Elhaj that they did not tolerate” tomfoolery.” Accordingly, I must convey gratitude to my supervisors for years of academic guidance, and the occasional "tomfoolery"-correction. For patient and valuable recommendations throughout this work.

Drs J. Zinsstag And Felix Roth from Swiss Tropical Institute provided unlimited support through their analytical model and other materials, without which this work could not have been presented in this manner.

The Ministry of Agriculture -Khartoum state- and the University of Sudan of Science and Technology contributed in funding. Special thanks are due to Dr.Faisal Hassan Ibrahim Minister of Agriculture, Animal resources and Irrigation- Khartoum State, Dr. Babiker Ateiya Kuku Scheme Director, Dr. Abdelwahid Mohamed Sharif General director of Animal Resources as well as Dr. Deyaa Eldeen Hassan Planning department.

I would like also to thank Staff members of The National Health Laboratory, first for their sincere collaboration in permitting me to utilize all their facilities and for their friendly attitude. Special thanks are extended to Dr. Nageeb Suliman Saeed, the General Manager of The National Health Laboratory not only for his great help but also for contacting colleagues to provide help. In this respect Prof. Musa Mohammed Khair of Faisal Professional Private Clinic was the Physician who examined the infected persons, cardinal gratitude on behalf of the patients and myself are extended to him.

The National Veterinary laboratory- Department of Brucella Provided the Rose Bengal antigen. Drs Rageb Mohammed Bakheit, Enaam Alsanossi and Nawaai contributed much in this respect . The Advice and Support of Prof. Osman Saad, and Dr. Fegiri were greatly appreciated.

I deem it a privilege to express my cardinal gratitude to Prof. Musa Tibin Ministry of Science and technology, Dr Hassan Mohammed Nur Ministry of

animal resources and Prof . Ahmed Ali Ismail University of Sudan of Science and Technology for their kind help, precious devotion and encouraging suggestions.

I owe thanks to colleagues in the private sector as well as the people of Kuku Scheme Dr Zubeeda ,Neama , Dr. Altaeib Alnour ,Osman , Hamid Samuel and Bekri.

My Younger brother and colleague Adil Abderahman created a stimulating environment. He and Miss Zenab were incredible in their dedication to this work.

Most importantly, my family has all sacrificed so that I could be a student:

My mother, husband, Anfal ,Amel, Sami, Amin, Rawan Elnour and Aam . I can never repay that debt.

ABSTRACT

The objective of this research is to quantify the impact of Brucellosis on Kuku Dairy scheme. Ecozoo model with introduction of some modifications was used as analytical framework. It provides the information needed to analyze the epidemiology of the disease in both animals and humans as well

as the economic analysis. Epidemiological data required were obtained from primary sources. These include two seroprevalence surveys for cattle, personal communications were also used as a source of primary data.

Two field surveys (including seroprevalence and socioeconomic surveys) were conducted during the period Jan- June 2004 . The Humans Brucellosis survey included 176 Volunteers from the population at risk. In the Bovine Brucellosis survey the sample design was based on two stages random sample design. In the first stage, holdings (the primary statistical units) were identified. Then the individual Animals (the Secondary Statistical units) were selected. The size of the primary Statistical units was calculated as 30.1 with $\alpha = 0.05$ and desired accuracy of (10). The number of animals examined was 574.

The laboratory diagnosis relied mainly on serological tests namely Rose –Bengal Test (RBT) as screening test and Competitive Enzyme linked Immuno- Sorbent Assay (c-ELISA) as confirmatory test. Tube agglutination test (TAT) was used as a routine test.

According to the confirmatory test : the herd prevalence rate is 90%, individual animal prevalence rate 24.9% and average within herd prevalence rate 24.5% (Sd 15.7 CI 4.088 at 95%). Based on c-Elisa human prevalence rate is 11.3% considering the seropositivity and 2.8% considering active brucella infection. Based on prevalence rates estimates on human parameters was found to be 18 active infected person in the baseline year and the infected cattle are 1508 head. These parameters were introduced into Ecozoo model. Data for DALYs calculation were obtained from primary sources as well as secondary sources.

Based on the epidemiological and economic data the total cost of the disease in both dairy and health sectors was found to be 65833570 SD out of which 65617120 SD was the cost of the dairy sector and 216450SD was the cost of health sector. Accordingly, the dairy sector Shouldered 99.97 % of the cost, while the health sector Shouldered 0.03% of Brucellosis cost in the base line year.

The burden of the disease was measured in DALYs. In the baseline year 18 persons were infected with Brucellosis . If we considered Brucellosis associated with level 0.1-disability weight, every infected person will loose 0.392659 year of his healthy life as a result of the infection. The total infected people will loose 7.067862 years of their healthy life. If the disease associated with level 0.2 disability weight, every infected person will loose 0.785318 years and the whole infected people will loose 14.13572 years of their healthy life.

Evolution of the disease was investigated in two scenarios. In scenario 1 the total animal population was left to grow at the normal rates. In this case the number of seropositive animals will increase with growth rate of 1.574 followed by the increase in number of actively infected humans with growth rate of 1.875.

The total cost of the disease in both dairy and health sectors were found to be 936445610SD (**665340905.8** SD in PV) over the 10 years, out of which 934974941SD (664219621.8SD in PV) was the cost of the dairy sector and 1610142 SD (1121284 SD in PV) was the cost of health sector.

The total loss of healthy years over the 10 years will account to 52.61631 years (0.1 DW). And 105.2326 years (0.2 DW).

In Scenario 11 the total number of animals was held constant. In this case the number of seropositive animals will increase during the 10 years with growth rate of 2.27. Followed by the increase in number of actively infected humans with growth rate of 3.667. The total cost of the disease in both dairy and health sectors was found to be **1321723709** SD (912709172SD in PV) over the 10 years, out of which 1319199296 SD (911003344SDPV) was the cost of the dairy sector and 2524413 SD (1705828 SD in PV) was the cost of health sector.

The total loss of healthy years over the 10 years will account to 82.06573 years (0.1 DW). And 164.1315 years (0.2 DW).

Most of the producers (80%) are well informed about the disease and its zoonotic nature, (53%) are well acquainted with the economic importance of the disease. All of them Support the idea of disease control.

The study confirm the endimicity of the scheme with both human and bovine Brucellosis.and prove the economic loss due to disease both financial and its burden on human heath.

The study recommends intervention to control the disease. Adoption of Whole herd Vaccination policy was recommended. Simulation of different intervention strategies to analyze the cost and benefits will help policy makers in setting up their priorities

الخلاصة

استهدفت الدراسة تقدير الخسائر الناتجة عن تفشي مرض البروسيلوزس بمشروع ألبان كوكو.

استخدمت الدراسة نموذج ال Ecozoo مع إجراء بعض التعديلات كأداة للتحليل. تم الحصول على البيانات المطلوبة من مصادرها الأولية والثانوية. للحصول على البيانات الأولية تم إجراء مسحين حقلين لجمع بيانات عن بر وسيلا الإنسان وآخر عن بر وسيلا الأبقار. أيضا تم استخدام أسلوب المقابلة الشخصية مع المنتجين و الخبراء لجمع البيانات الأولية.

تم إجراء مسح بر وسيلا الإنسان في الفترة ما بين يناير إلى يونيو 2004 حيث جمعت عينات للدم من 176 متبرع بالإضافة الى البيانات المطلوبة.

اعتمد التشخيص المعمل على اختبارات المصل بالتحديد اختبار الروز بنغال ككاشف مسحي واختبار c-ELISA كاختبار تأكيدي. أخضعت العينات أيضا لاختبار TAT اختبار روتيني يجرى بالسودان.

لتقدير عبء المرض على الإنسان تم استخدام مؤشر غير نقدي (زمني) يعرف بسنوات التعطيل المعدلة .

بالنسبة لبر وسيلا الأبقار تم اختيار العينة على مرحلتين ، في المرحلة الأولى تم اختيار الحيازات (القطعان) عشوائيا. في المرحلة الثانية تم اختيار الوحدات الإحصائية (الحيوانات). استهدفت الدراسة كل الأبقار البالغة. بلغ عدد الحيازات المختارة 30 حيازة بينما بلغ عدد الأبقار 574 . حيث تم اخذ العينات وفحصها بواسطة اختبار الروز بنغال و c-ELISA .

فيما يتعلق بانتشار المرض توصلت الدراسة الى النتائج التالية:

بلغ معدل انتشار المرض في الانسان 11.3% . بناء على ايجابية اختبار المصل و 2.8% بناء على الإصابة الحقيقية.

بالنسبة للأبقار بلغ معدل انتشار المرض في القطعان 90% ، معدل الانتشار بين الأبقار 24.9% ومتوسط معدل الانتشار داخل القطيع 24.5% .

بناء على هذه المعدلات بلغ تقدير عدد الأشخاص المصابين في سنة الأساس 18 شخصا وعدد الأبقار المصابة 1508 . بلغ تقدير الخسائر الناجمة عن المرض ب67126953.8 دينار (سبعة وستون مليونا ومائه ستة وعشرون ألفا وتسعمائة ثلاث خمسون دينار). منها 66910503.8 دينار (ستة وستون مليونا ستمائة وعشرة ألفا وخمسمائة وثلاث دينار) خسائر قطاع الألبان. بينما بلغت الخسائر في قطاع الصحة 216450 (مائتان وأربعة عشر ألفا وأربعمائة

وخمسون دينار). عليه فان قطاع الألبان يتحمل 99.76 % من تكلفة المرض بينما يتحمل قطاع الصحة 0.33% من التكلفة .

فيما يتعلق بالعبء الصحى على الإنسان، توصلت الدراسة الى أن الفرد المصاب يفقد 0.392659 من سنوات عمره المعافاة اذا ارتبط المرض بوزن التعطيل 0.1، و 0.785318 سنة إذا ارتبط المرض بالوزن 0.2 ، وعليه يبلغ عدد سنوات العمر المعافاة النى يفقدها المصابون فى الحالة الأولى 7.067862 سنة و 14.13572 سنة فى الحالة الثانية.

بحثت الدراسة تطور المرض خلال 11 سنة من خلال سيناريو هين ، فى السيناريو الاول ترك العدد الكلى للحيوانات ينمو وفق المعدلات الجارية. فى هذه الحالة فان عدد الحيوانات المصابة سوف ينمو بمعدل 103.2% و ينمو عدد الأفراد المصابين بمعدل 27.8% وتكون تكلفة المرض الكلية فى خلال إحدى عشر سنة (2004-2014) 1022123020 دينار 745547286 دينار بالقيمة الحالية. ما يعادل 4088492.08 دولار .

بلغ عدد سنوات العمر المعافاة المفقودة إحدى عشر سنة 59.7 سنة بوزن 0.1 و119.4 سنة بوزن 0.2 .

أجرى السيناريو الثانى بافتراض ثبات العدد الكلى للحيوانات. فى هزة الحالة فان عدد الحيوانات المصابة سوف يزيد بمعدل 258.1% فى خلال إحدى عشر سنة بينما يزيد عدد الأفراد المصابين أصابه فعليه 133%. تبلغ التكلفة الكلية للمرض 1414827570 دينار SD101505075 دينار بالقيمة الحالي. ما يعادل 5655170.142 دولار .

يقدر الفقد الكلى لسنوات العمر المعافاة ب 89.1 سنة بوزن 0.1 و 178.3 بالوزن 0.2 . توصلت الدراسة الى أن معظم المنتجين (80%) لديهم العلم الكافي بالمرض وطبيعته المعدية للإنسان. وأن (53%) منهم يدركون أهميته الاقتصادية. أكدت الدراسة استيطان المرض بالمشروع وأثبتت الخسائر الناجمة عنه. كما أوضحت تطور المرض والخسائر الناتجة عن ذلك عند عدم السيطرة عليه فى خلال إحدى عشر سنة. أوصت الدراسة بالتدخل للسيطرة على المرض فى الحيوان وذلك بإتباع سياسة التطعيم الكلى للقطيع ثم تطعيم العجول سنويا والحيوانات البالغة كل سنتين لمدته عشر سنوات ثم إتباع سياسة الفحص وذبح الحيوانات الموجبة. وذلك بعد مضاهاة الاستراتيجية المختارة

بمعدلات مختلفة لكفاءة المصل لتحديد نسبة التكاليف والمنافع مما يساعد متخذي القرار في اختيار
البديل المناسب .

Table of Contents

Page

35

<i>Dedication</i>	
<i>Acknowledgements</i>	
<i>English abstract</i>	
<i>Arabic abstract</i>	
<i>Table of Contents</i>	
<i>List of Tables</i>	
<i>List of equations List</i>	
<i>List of Figures</i>	
<i>List of abberiviations</i>	
<i>List of Maps</i>	
<i>List of appendices</i>	
Chapter One:Introduction	1
1-1 Background	1
1-2 Dairy sub-sector in Sudan	4
1-3 Problem statement	6
1-4 Rationale of the Research	7
1-5 The Research Objectives	7
1-6 The research hypotheses	8
1-7 Time and place of the research	8
1-8 Research layout	8

Chapter Two: Literature Review

2.1.1 Animal health economics	10
2.1.2 Economics of animal health.	16
2-3 The burden of disease.	19
2.2.1. Disability adjusted life years (DALYS).	20
2.2.2. Calculating DALYs.	22
2.2.3. Calculation of DALYS with discounting and age weighting.	23
2-3 Zoonosis.	25
2.4 Brucellosis.	26
2.4.1 Economic importance of brucellosis	28
2.4.2. Bioterrorism of Brucella	29
2.4.3 Bovine Brucellosis	30
2.4.3.1 Epizootiology of Bovine Brucellosis	30

2.4.3.2. Transmission in animals	31
2.4.3.3. Clinical signs	32
2.4.3.4. Diagnosis of Bovine Brucellosis	33
2.4.3.5. Treatment of Bovine Brucellosis	37
2.4.3.6. Control and Eradication of Bovine Brucellosis	38
2.4.3.7. A review of some control programs	42
2.4.4. Human Brucellosis	45
2.4.4. 1. Historical Background	45
2.4.4. 2. Epidemiology of Human Brucellosis	46
2.4.4. 3. Transmission of Human Brucellosis	47
2.4.4. 4. Clinical signs of Human Brucellosis	48
2.4.4. 5. Pathogenesis of Human Brucellosis	49
2.4.4. 6. Diagnosis of Human Brucellosis	51

2.4.4. 7. Medications	53
2.4.4. 8. Control Measures	54
2.4.5. Brucellosis in Sudan	54
2.4.6. Experience of Arab Company for Agricultural Production and Processing (ACAPP) in eradication of bovine brucellosis	56
2.4.7. Relevant studies	57
2.4.7. 1. Bovine Brucellosis	57
2.4.7. 2. Human Brucellosis	59
2.4.8. Economic assessments of Brucellosis	62
<i>Chapter Three: Materials and Methods</i>	64
3-1 The study area	64
3-2 The methodology of data collection	67

3-2-1 Primary Data	68
3-2-1-1 Data collection concerning Bovine Brucellosis	69
3-2-1-2 Data collection concerning Human Brucellosis	71
3-3- Laboratory diagnosis	73
3-4 The analytical framework	78
3-4-1 The Ecozoo Model	78
3-4-2 Kuku model as a modification of Ecozoo	83
3-5 Computations	88
Chapter Four : Results	91
4-1 Bovine Brucellosis:	91
4-1-1 The Sample Size and design	91
4-1-2 The Study population	91
4-1-3 Prevalence of Bovine Brucellosis	92
4-1-3-1 Screening rate using RBT	92
4-1-3-2 confirmation rates in c-Elisa for RBT positive samples	92
4-1-4 Fitting Data to the deterministic-transmission model	94
4-2 Human Brucellosis	95
4-2-1 The sample size:	95
4-2-2 the study population`	95
4-2-3 Prevalence of Human Brucellosis	95
4-2-3-1 Screening rate using RBT	95
4-2-3-2 confirmation rates in c-Elisa	96
4-2-3-3 Confirmation rates in TAT	96
4-3 Fitting data to the model	98
4-3-1 Baseline year estimates:	98

4-3-1-1	Cost of Brucellosis in the dairy Sector	99
4-3-1-2	Impact of Brucellosis on health sector	100
4-3-1-3	Cost Sharing between the two Sectors	101
4-3-1-4	The burden of human brucellosis in kuku scheme in DALYS	102
4-4	Evolution of the disease over 11 years	103
4-4-1	Scenarios 1	103
4-4-1-1	Impact of Brucellosis	110
4-4-1-1-1	Impact of Brucellosis on dairy sector	110
4-4-1-1-2	Impact of Brucellosis on Health sector	111
4-4-1-1-3	Impact of Brucellosis on Dairy and Health sectors	112
4-4-1-1-4	The burden of Brucellosis	112
4-4-2	Scenario 11	113
4-4-2-1	Impact of Brucellosis:	119
4-4-2-1-1	Impact of Brucellosis on dairy sector	119
4-4-2-1-2	Impact of Brucellosis on Health sector	121
4-4-2-1-3	Impact of Brucellosis on Dairy and Health sectors	122
4-4-2-1-3	The Burden of Brucellosis	123
4-5	Producer knowledge about the disease and their attitude towards disease control	124
Chapter five : Discussion		126
5-1	Prevalence of Bovine Brucellosis	126
5-2	Prevalence of Human Brucellosis	128
5-3	The Model	129
5- 4	Evolution of Bovine Brucellosis over 11 years (scenario 1)	132

5-5	Evolution of Human Brucellosis over 11 years scenario 1)	133
5-6	Impact of Brucellosis:	134
5-7	The burden of Brucellosis in Kuku scheme:	135
5-8	Control of bovine Brucellosis in Kuku scheme:	136
	<i>Chapter six: Conclusions and recommendations</i>	<i>138</i>
	References	
	Appendices	

LIST OF TABLES

<i>Table</i>	<i>content</i>	
<i>page</i>		
Table 1-1	Estimated milk production in Sudan (2004)	5
Table 1-2	Milk gap from domestic production	5
Table 1-3	Quantity and Value of Milk products import 1999-2001	6
Table 4-1	Herd Composition in Kuku dairy Scheme	92
Table 4-2	Herd prevalence in kuku Scheme based on RBT & c-Elisa	92
Table 4-3	Individual Animal prevalence in kuku Scheme based on RBT& c-Elisa	94
Table 4- 4	Screening test (RBT) results of human sera	96
Table 4- 5	Confirmatory rates of human sera in c-Elisa	97

Table 4- 6	Confirmatory rates of human sera in TAT	97
Table 4- 7	Confirmatory rates of C-elisa and TAT on RBT	98
Table 4- 8	Baseline estimates for brucellosis deterministic transmission model between cattle and from cattle to humans	98
Table 4-9	Quantity & Value of milk lost due to Brucellosis in Kuku cooperative scheme in the baseline year (2004)	99
Table 4-10	Number & Value of meat lost due to Brucellosis in Kuku cooperative scheme in the baseline year (2004)	100
Table 4- 11	Total losses due to Brucellosis in the Dairy Sector	100
Table 4-12	The Financial cost of Human Brucellosis in the baseline year	101
Table 4-13	Cost Sharing between dairy and Health sectors	102
Table 4-14	The burden of Human brucellosis in Kuku Scheme in Dalys	
Table 4-15	Estimated Parameters of Brucellosis transmission between Cattle and from cattle to humans in kuku Scheme	104
Table 4-16	Evolution of Bovine Brucellosis in kuku scheme over 11 year (2004-2014) with growing animal population	105
Table 4-17	Growth rates of Susceptible, Seropositive and total animal population in 11 years	107
Table 4-18	Evolution of human brucellosis over 11 years	108

	(2004-2014) with growing animal population	
Table 4-19	Growth rates of Susceptible, infected, immune and in contact human in 11 years	108
Table 4-20	Value of milk and calves lost due to Brucellosis In Kuku cooperative scheme over 11 years	110
Table 4-21	Present value of milk and calves lost due to brucellosis in Kuku cooperative scheme over 11 years	111
Table 4-22	Cost of Brucellosis to health Sector	111
Table 4- 23	The total cost of Brucellosis in Dairy & Health Sector over 11 years	112
Table 4-24	The burden of Human Brucellosis over 11 years in Kuku scheme (Scenario 1)	113
Table 4-25	Evolution of Bovine Brucellosis in kuku scheme over 11 year with constant animal population	115
Table 4-26	Growth rates of Susceptible, seropositive and total animal population in 11 years	116
Table 4-27	Evolution of Human Brucellosis over 11 year with constant animal population	116
Table 4-28	Growth rates of Susceptible, infected, immune and in contact human in 11 years with constant animal population	119
Table 4-29	Value of milk and calves lost due to Brucellosis in Kuku cooperative scheme over the 11 years	120
Table 4-30	Present value of milk and calves lost due to Brucellosis	121

in Kuku cooperative scheme over 11 years

Table 4- 31	Cost of Brucellosis in health Sector	122
Table 4- 32	Cost of Brucellosis in Dairy and Health Sectors in Kuku cooperative scheme over 11 years	123
Table 4- 33	The burden of Human Brucellosis in Kuku scheme with constant animal population	124

List of equations

$$1/n = 1/nX + 1/N \quad (1)$$

$$Z \cdot st(p) = Z \{ (P \cdot q/n) (N-n)/N \}^{1/2}$$

(2)

$$\alpha_c(\text{effective}) = \alpha_c(\text{baseline}) (1 - (\eta)) (Y / X+Y)$$

(3)

$$I \text{ncidence}_{\text{cattle}} = \gamma_c \beta_c XY \quad (4)$$

$$dx/dt = \alpha_c (X+Y)(1 - (\eta (Y/(X+Y)))) - \mu_c X - \gamma_c \beta_c XY \quad (5)$$

$$dY/dt = \gamma_c \beta_c XY - \mu_c X \quad (6)$$

$$dA/dt = v_h (A+B+C) + \lambda C - (\gamma_c \beta_{ch} AY) - \mu_h A \quad (7)$$

$$dB/dt = (P \gamma_c \beta_{ch} AY) - \kappa B - \mu_h B \quad (8)$$

$$dC/dt = (1-P) \gamma_c \beta_{ch} AY + \kappa B - \lambda C - \mu_h C \quad (9)$$

$$YLD = DW \left\{ \frac{K C e^{ra}}{(r+\beta)^2} \left[e^{-(r+\beta)(L+a)} \left\{ -(r+\beta)(L-a) - 1 \right\} - e^{-(r+\beta)a} \left\{ -(r+\beta)a - 1 \right\} \right] + \frac{1-K}{r} (1-e^{-rL}) \right\} \quad (10)$$

$$(r+\beta)^2$$

r

LIST OF FIGURES

<i>Figure</i>	<i>contents</i>	<i>page</i>
Fig. 1	Kuku deterministic transmission model	
Fig. 2	Herd composition in Kuku scheme	
Fig. 3	Individual Animal prevalence in kuku Scheme based on RBT& c-Elisa	
Fig. 4	Results of humans sera in RBT, C-elisa and TAT	
Figure 5a	Evolution of bovine brucellosis in Kuku Scheme over 10 years (2005-2014) with growing animal population	
Figure 5b	Incidence of bovine brucellosis and the change in the number of Susceptible and Seropositive animals over 10 years (2005- 2014)with growing animal population	
Fig. 6a	Evolution of human Brucellosis in Kuku scheme over 10 years(2005-2014) with growing animal	
Fig. 6b	Change in the number of susceptible, infected and Immune humans in Kuku scheme over 10 years with growing animal population	
Fig. 6b	Incidence of bovine brucellosis and change in the number of Susceptible and seropositive animal with constant animal population	
Fig. 7a	Evolution of Bovine Brucellosis in Kuku scheme over 10 years (2005-2014) with constant animal population	
Fig. 7b	Incidence of bovine brucellosis and change in the number of Susceptible and seropositive animal with constant animal population	

- Fig. 8a Evolution of human Brucellosis in Kuku scheme over 10 years (2005-2014) with constant animal population
- Fig. 8b Change in the number of susceptible, infected and Immune humans in Kuku schem with constant animal population

LIST OF ABBREVIATIONS

ACAPP	Arab Company for Agriculture production and processing
ASA	Applied science and analysis
BBAT	Buffered Brucella antigene tests
BEP	Brucellosis Eradication Program
BTB	Bovine tubercullosis
Cc	Conjugate control
CELISA.	Competitive Enzyme Linked Immuno- sorbent Assay.
CDC	The Centers for Disease Control and Prevention
CNS	Central Nervous Sytem
CF	Complement fixation

DALYs.	Disability-adjusted life years
Defra	Department for Environmental, Food and Rural Affairs
DW	Diability weight
FAO	Food and Agriculture Organization
GATT	General agreement on Trade and Tariff
GU	Genitourinary
H2O2	Hydrogen peroxide
HR P	Horse- radish peroxidase
IELISA	Indirect Enzyme Linked Immuno- sorbent Assay
ICFTU	International Complement Fixation Unit
IM	Intra muscular
IMI	intramammary infusion
IV	Intravenous
KCDFs	Kuku cooperative dairy farms
LA-OTC	long-acting oxytetracycline
LDCs	Less developing countries
LDPS	livestock development planning system
M.D	Medical Doctor
MAb	Monoclonal. Antibody
MMWR	Mortality and Morbidity Weekly Report
MRT	Milk Ring Test
OD	Optical density

OIE	Office International des Epizooties
PBS	Phosphate buffer saline
PCR	polymerase chain reaction
PI	percentage inhibition
PO	Per Oss
PP	per cent positivity
RBSA	Rose-Bengal slide agglutination
RBT	Rose –Bengal Test
SAT	Serum agglutination test
S-LPS	Smooth Lipopoly Saccaride
ST	streptomycin
STA	Standard tube agglutination
TAT	Tube Agglutination Test
TMP-SMZ	trimethoprim/sulfamethoxazole
WHO	World Health Organization
WTO	World Trade Organization

LIST OF MAPS

Map	page
3- The Republic of Sudan	
4- Khartoum State	

List of Appendices

- Appendix 1 Bovine Brucellosis distribution Table
- Appendix 2 Questionnaire sheet for bovine brucellosis survey in Kuku Dairy
Co-operative Scheme, Khartoum North, Sudan, 2004.
- Appendix 3 Data included in individual cow Master sheet
- Appendix 4 Data included in Human brucellosis Master sheet.
- Appendix 5 Sources of data.
- Appendix 6 The animals sample size.
- Appendix 7 Model for joint human-animal brucellosis transmission in
Mongolia after Roth et al., (2003), with permission from the
Bulletin of the World Health Organization.
- Appendix 8 Differential equations for the fitting and simulation of
vaccination.

